<DOC>
	<DOCNO>NCT01085630</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . PURPOSE : This randomized phase II trial study well pemetrexed disodium observation work treat patient malignant pleural mesothelioma without progressive disease first-line chemotherapy .</brief_summary>
	<brief_title>Pemetrexed Disodium/Observation Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maintenance therapy pemetrexed disodium versus observation improve progression-free survival patient malignant pleural mesothelioma least stable disease completion first-line therapy comprise pemetrexed disodium cisplatin carboplatin . Secondary - To determine overall survival patient treat regimen versus observation . - To evaluate frequency response patient treat regimen . - To assess toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord first-line chemotherapy regimen ( cisplatin/pemetrexed disodium v carboplatin/pemetrexed disodium ) , histologic subtype ( epithelioid v ) number course receive ( &lt; 6 vs 6 ) . - Arm I : Patients receive pemetrexed disodium IV 10 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation disease progression . After completion study therapy , patient follow every 6 month 3 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm malignant pleural mesothelioma meeting 1 follow cell type : Epithelial Sarcomatoid Mixed type Histologically document malignant pleural mesothelioma , epithelial , sarcomatoid mixed type , amenable surgical resection Prior treatment Currently receive firstline treatment pemetrexed + platinum ; patient register Cancer Leukemia Group B ( CALGB ) 30901 late last day cycle 4 first line therapy Prior intracavitary cytotoxic sclerosing therapy ( include bleomycin ) acceptable ; prior intrapleural cytotoxic chemotherapy consider systemic chemotherapy Prior surgical treatment allow Prior radiation therapy allow Nonpregnant nonnursing ; woman child bear potential men must agree use appropriate method birth control throughout participation study ; appropriate method birth control include abstinence , oral contraceptive , implantable hormonal contraceptive ( Norplant ) , double barrier method ( diaphragm plus condom ) RANDOMIZATION ELIGIBILITY CRITERIA Patients complete response , partial response , stable disease follow 4 , 5 6 cycle firstline chemotherapy pemetrexed AND either cisplatin carboplatin ; maximum 6 cycle chemotherapy may give Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Granulocytes &gt; = 1,500/ul Platelet count &gt; = 100,000/ul Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2 x ULN Calculated creatinine clearance &gt; = 45 ml/min Disease amenable surgery Must enrol image protocol CALGB580903 Complete response , partial response , stable disease completion 4 course firstline chemotherapy comprise pemetrexed disodium AND cisplatin carboplatin Study therapy begin within 9 week follow day 1 cycle 4 firstline treatment No clinically significant pleural peritoneal effusion adequately manage drainage pemetrexed disodium PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week Granulocytes ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2 time ULN Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness would prevent patient give informed consent No second malignancy except nonmelanoma skin cancer carcinoma situ cervix unless curatively treat evidence active disease ≥ 5 year No medical condition , opinion treat physician , would make study treatment unreasonably hazardous patient include , limited , follow : Ongoing active infection HIV positivity Inability take oral medication Psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior intracavitary cytotoxic sclerosing therapy ( include bleomycin ) allow Prior intrapleural cytotoxic chemotherapy consider systemic chemotherapy Prior surgery allow Prior radiotherapy allow No concurrent palliative radiotherapy No concurrent hormone chemotherapeutic agent except follow : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic premedication pemetrexed disodium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
	<keyword>stage II malignant mesothelioma</keyword>
	<keyword>stage III malignant mesothelioma</keyword>
	<keyword>stage IV malignant mesothelioma</keyword>
</DOC>